title: [Pharmacotherapy of osteoporosis accompanied by lifestyle-related diseases].
abstract: Lifestyle-related diseases, such as diabetes mellitus, hypertension and dyslipidemias, are often accompanied by osteoporosis. Treatment of osteoporosis in such cases is essentially the same as that for primary osteoporosis, but it is important to be aware of the interference between osteoporosis treatment and the drugs used for the lifestyle-related diseases. Raloxifene, bisphosphonates and activated vitamin D are commonly used for treatment of osteoporosis, and they are reported to have a positive effect on atherosclerosis. Beta-blocker use, particularly selective beta-blocker, is associated with reduced fracture risk. Statin is also reported to stimulate bone formation via bone morphogenetic protein-2 expression, but their clinical utility has not yet been confirmed. One class of antidiabetic drugs, thiazolidinediones, causes bone loss and further increases fracture risk, placing thiazolidinediones in the category of drugs causing secondary osteoporosis.
authors.affiliation: Center for Promotion of Clinical Investigation, Tokyo Metropolitan Geriatric Hospital.
authors.forename: Seijiro
authors.initials: S
authors.lastname: Mori
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D048909:Diabetes Complications / Q000188:drug therapy / Q000209:etiology; D004164:Diphosphonates / Q000627:therapeutic use; D050171:Dyslipidemias / Q000188:drug therapy / Q000209:etiology; D050723:Fractures, Bone / Q000139:chemically induced; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D007004:Hypoglycemic Agents / Q000009:adverse effects; D008019:Life Style; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000009:adverse effects; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D004164:Diphosphonates; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014807:Vitamin D; D020849:Raloxifene Hydrochloride; C089946:2,4-thiazolidinedione